Loading...
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML
Hills, Robert Burnett, Alan Lucas, Claire Scott, Laura Carmell, Natasha Holcroft, Alison Clark, Richard E.
Hills, Robert
Burnett, Alan
Lucas, Claire
Scott, Laura
Carmell, Natasha
Holcroft, Alison
Clark, Richard E.
Citations
Altmetric:
Advisors
Editors
Other Contributors
EPub Date
Publication Date
2018-04-27
Submitted Date
Collections
Files
Loading...
Main article
Adobe PDF, 800.16 KB
Other Titles
Abstract
Key Points
PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients.
AKTS473 phosphorylation is a predictor of survival, and diagnostic levels of AKTS473 could be a novel biomarker in AML.
Citation
Lucas, C. M., Scott, L. J., Carmell, N., Holcroft, A. K., Hills, R. K., Burnett, A. K. & Clark, R. E. (2018). CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood advances, 2(9), 964-8.
Publisher
American Society for Hematology
Journal
Blood Advances
Research Unit
PubMed ID
PubMed Central ID
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
2473-9529
2473-9537
2473-9537